XGN

Exagen Inc. Announces Changes to the Board of Directors

Retrieved on: 
Friday, April 26, 2024
University, Commoner, Rady Children's Hospital, Hospital, Champaign–Urbana metropolitan area, Churchill College, Cambridge, XGN, Privacy, SVP, Genetic distance, Growth, Postdoctoral researcher, Management

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.

Key Points: 
  • CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
  • Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director.
  • “First, I want to thank Brian Birk, Beto Pallares, Ph.D. and Wendy Johnson for their years of commitment and service to the Exagen Board of Directors.
  • To ensure we are well-equipped to grow with these changes, we have appointed Dr. Kahn to our Board of Directors.

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Retrieved on: 
Friday, March 8, 2024
XGN, Medtech

CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.

Key Points: 
  • CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in one-on-one meetings with investors and a fireside chat on Wednesday, March 20, at 1:30 PM ET.

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Retrieved on: 
Thursday, March 7, 2024
Interest, XGN, Webcast, Cryptocurrency

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024.

Key Points: 
  • CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).
  • A replay of the conference call will be available until Monday, April 1, 2024, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Tuesday, January 30, 2024
Digital health, Conference, XGN

CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah.

Key Points: 
  • CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Retrieved on: 
Sunday, January 7, 2024
ASP, Bank statement, Depreciation, XGN, Net, CTD, GAAP, Cryptocurrency

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.

Key Points: 
  • CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
  • The company reaffirms its full-year 2023 total revenue guidance of at least $50 million and full-year 2023 non-GAAP adjusted EBITDA guidance of approximately negative $20 million.
  • The company is providing the above preliminary financial information and results of operations as of and for the year ended December 31, 2023, based on currently available information.
  • As a result, the company’s final results may vary from the preliminary results presented above.

Exagen Inc. Reports Strong Third Quarter 2023 Results

Retrieved on: 
Monday, November 13, 2023
Johns Hopkins University, Webcast, EBITDA, Interest, SAN, LLP, Bank statement, BDO, Net, Depreciation, ASP, XGN, GAAP, Lupus nephritis, Growth, Medicare, Biomarker, CTD, Coal, Bookkeeping, Video game, Bank, Lipotriches exagens

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.
  • Revenue was $13.4 million for the third quarter of 2023, compared with $14.7 million in the third quarter of 2022 and $14.1 million in the second quarter of 2023.
  • Gross margin was 57.4% in the third quarter of 2023, compared to 58.7% in the second quarter of 2023 and 59.2% in the third quarter of 2022.
  • A conference call to review third quarter 2023 financial results and to provide a business update is scheduled for today, November 13, 2023, at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen Inc. Reports Strong Second Quarter 2023 Results

Retrieved on: 
Monday, August 7, 2023
Interest, Webcast, Medicare, ASP, CTD, XGN, Rheumatology, SAN, Video game, Cryptocurrency, Lipotriches exagens

Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.

Key Points: 
  • Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.
  • Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023.
  • Gross margin was 58.7% in the second quarter of 2023, compared to 47.2% in the first quarter of 2023 and 20.1% in the second quarter of 2022, primarily due to increased accrual rates due to improved collections from prior periods.
  • For the second quarter of 2023, net loss was $5.0 million, compared to a net loss of $7.7 million in the first quarter of 2023 and a net loss of $14.7 million in the second quarter of 2022.

Exagen Inc. Appoints Paul Kim to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Learning, University, COVID-19, XGN, Certified Public Accountant, Accounting, Genetics, SAN, Autoimmune disease, Berkeley, Growth, Management, Lipotriches exagens

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.

Key Points: 
  • SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.
  • Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (Nasdaq: FLGT), a full-service genomic testing company built around a foundational technology platform.
  • “We are thrilled to welcome Paul to our Board of Directors at Exagen.
  • “I look forward to learning from his 30 plus years of leadership in business.”
    “I am delighted to join the Board of Directors at Exagen,” said Paul Kim.

Mindera Health™ Announces Change to Executive Leadership Team

Retrieved on: 
Thursday, May 11, 2023
Lupus, Gastroenterology, Employment, Prognosis, XGN, SLE, Biomarker, Psoriasis, Towson University, Acquisition, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Patient, Physician, Medicine, R, Health, III, Human, Rheumatoid arthritis, Disease, Management, Pharmaceutical industry, Prometheus, Marketing

San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.

Key Points: 
  • San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team.
  • The company has announced industry veteran Ron Rocca will succeed George Mahaffey as President and Chief Executive Officer.
  • Mr. Mahaffey, who joined the company in 2020, helped lead the company’s transition from the R&D stage through the commercial launch of Mindera Health’s first test.
  • “On behalf of the board, I want to thank George for his valuable contributions to Mindera Health,” said Joe Cook, III, Chairman of Mindera Health and Co-Founder and Managing Director of Mountain Group Partners.

Exagen Inc. Reports Third Quarter 2022 Results

Retrieved on: 
Monday, November 14, 2022
COVID-19, Growth, SAN, Laboratory, Rheumatology, R, Physician, Patient, Lupus, Janssen, Movement, Total, Annual report, XGN, CTD, Medicine, Webcast, Security (finance), Medicare, Interest, Precision medicine, Research, Therapy, PLA, Investment, Audit committee, Renewable energy, Video game, Tutoring, Pharmaceutical industry, Lipotriches exagens

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022.
  • Delivered 35,569 AVISE CTD tests, including AVISE Lupus, in the third quarter of 2022, a 12% increase over the third quarter of 2021.
  • Number of ordering healthcare providers totaled 2,287 in the third quarter of 2022, an increase of 16% over the third quarter of 2021.
  • Testing gross margin was 59.2% in the third quarter of 2022, compared to 53.7% in the third quarter of 2021.